Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

35
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
35
Nephrotic Syndrome I : Introduction01:24

Nephrotic Syndrome I : Introduction

72
Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...
72
Autoimmune Disorders01:29

Autoimmune Disorders

792
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
792
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

109
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
109
Secondary Lymphoid Organs01:15

Secondary Lymphoid Organs

5.6K
Secondary organs, including lymph nodes, the spleen, and mucosa-associated lymphoid tissue (MALT), work harmoniously to protect us from disease and infection.
The spleen is a vital organ in the lymphatic system, nestled in the upper left side of the abdomen. It is composed of two primary regions: the red pulp and the white pulp, each having distinct functions. The red pulp performs a significant role in blood filtration. It efficiently purges the blood of old or damaged red blood cells and...
5.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Fertility, pregnancy and lactation in women with systemic lupus erythematosus.

Nature reviews. Rheumatology·2026
Same author

Patient-physician discordance in assessing SLE disease activity: longitudinal analysis of disease-related variables and quality of life.

Rheumatology (Oxford, England)·2025
Same author

A 6-year prospective study on work participation and the associated factors in Dutch patients with systemic lupus erythematosus (SLE).

Arthritis research & therapy·2025
Same author

Advancing treat-to-target in SLE: a pilot study using a clinical decision support system.

Lupus science & medicine·2025
Same author

Failing maternal-fetal tolerance in SLE (FaMaLE): a prospective cohort study for finding the molecular mechanisms behind pregnancy complications.

Lupus science & medicine·2025
Same author

Dialogue: Antiplatelet effects of hydroxychloroquine in patients with systemic lupus erythematosus evaluated by the total thrombus-formation analysis system (T-TAS).

Lupus science & medicine·2024
Same journal

Vaccination coverage of influenza and pneumococcal vaccines in patients with rheumatic diseases: a systematic review and meta-analysis.

Rheumatology (Oxford, England)·2026
Same journal

Comment on: Distinct cytokine and cytokine receptor expression patterns characterise different forms of myositis.

Rheumatology (Oxford, England)·2026
Same journal

A Delphi survey of patients and clinicians on a unified and stratified approach to managing GCA-PMR spectrum disease.

Rheumatology (Oxford, England)·2026
Same journal

Cardiac involvement in Behçet's syndrome: findings from a clinically driven cardiological evaluation.

Rheumatology (Oxford, England)·2026
Same journal

Mechanisms, clinical manifestations and management of cardiovascular diseases in ANCA-associated vasculitis.

Rheumatology (Oxford, England)·2026
Same journal

Clinical and autoantibody associations with malignancy in systemic sclerosis: A systematic review and meta-analysis.

Rheumatology (Oxford, England)·2026
See all related articles

Related Experiment Video

Updated: Oct 8, 2025

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice
12:04

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice

Published on: November 1, 2015

18.0K

New developments in systemic lupus erythematosus.

Michel W P Tsang-A-Sjoe1, Irene E M Bultink1

  • 1Department of Rheumatology, Amsterdam Rheumatology and immunology Center, Amsterdam University Medical Center, Amsterdam, The Netherlands.

Rheumatology (Oxford, England)
|December 24, 2021
PubMed
Summary
This summary is machine-generated.

Recent clinical trials show promising new treatments for systemic lupus erythematosus (SLE). Belimumab, the first biologic for SLE, met its endpoint, and new targeted therapies are emerging, offering hope for personalized medicine.

Keywords:
SLEbiologic therapiestargeted therapiestherapy

More Related Videos

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice
09:43

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice

Published on: June 8, 2022

3.1K
Dermoscopy Aids in the Diagnosis of Discoid Lupus Erythematosus
05:39

Dermoscopy Aids in the Diagnosis of Discoid Lupus Erythematosus

Published on: May 16, 2025

261

Related Experiment Videos

Last Updated: Oct 8, 2025

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice
12:04

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice

Published on: November 1, 2015

18.0K
Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice
09:43

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice

Published on: June 8, 2022

3.1K
Dermoscopy Aids in the Diagnosis of Discoid Lupus Erythematosus
05:39

Dermoscopy Aids in the Diagnosis of Discoid Lupus Erythematosus

Published on: May 16, 2025

261

Area of Science:

  • Immunology
  • Rheumatology
  • Clinical Trials

Background:

  • Systemic lupus erythematosus (SLE) is a complex autoimmune disease with limited treatment options.
  • Past decades saw numerous unsuccessful clinical trials for SLE therapeutics.
  • Recent advances in understanding SLE pathophysiology have identified new therapeutic targets.

Purpose of the Study:

  • To review recent and ongoing clinical trials for SLE treatments.
  • To highlight novel therapeutic strategies emerging from improved disease understanding.
  • To assess the potential of new SLE drugs in clinical development.

Main Methods:

  • Review of published data from recent and ongoing clinical trials in SLE patients.
  • Analysis of emerging therapeutic targets based on SLE pathophysiology.
  • Evaluation of drug classes including biologics and small molecules.

Main Results:

  • Belimumab, a biologic targeting B cells, was the first SLE-specific drug to meet its primary endpoint.
  • New biologics targeting B cells, T cells, and type 1 interferons are in development.
  • Small molecules inhibiting kinases and therapies restoring immune tolerance show promise.

Conclusions:

  • Promising results from Phase II and III trials suggest potential approval of new SLE therapies.
  • Advancements in SLE treatment are moving towards more personalized medicine approaches.
  • Future treatments aim to restore immunological balance and offer tailored options for SLE patients.